<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4862">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198366</url>
  </required_header>
  <id_info>
    <org_study_id>C-029-402</org_study_id>
    <nct_id>NCT01198366</nct_id>
  </id_info>
  <brief_title>Study of AERAS-402 in Healthy Infants</brief_title>
  <official_title>A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aeras</source>
  <oversight_info>
    <authority>Kenya: Pharmacy and Poisons Board</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Mozambique: Ministry of Health (MISAU)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AERAS-402 will be given to infants of at least 16 weeks of age who have already been
      vaccinated with BCG to determine if AERAS-402 will increase protection of infants to
      tuberculosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The only currently available tuberculosis vaccine, bacillus Calmette-Guérin (BCG), is
      estimated to reduce the risk of tuberculosis (TB) in children by up to 70-80%, but
      protection is incomplete. Efforts to increase TB protection in children include new vaccines
      for primary immunizations as well as combinations of vaccines given as primary and boosting
      vaccinations.

      AERAS 402 is a live recombinant serotype 35 replication deficient adenovirus vector
      expressing a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens (Ag85A, Ag85B
      and TB10.4). It presents Mtb antigens in the setting of a new, live, replication-deficient
      adenovirus vaccine that may increase T cell-mediated immunity and thus protection from
      tuberculosis. AERAS-402 appears safe and immunogenic in adults. Since BCG-vaccinated infants
      are the population for which AERAS-402 might be indicated, AERAS-402 will be administered to
      infants of at least 16 weeks of age who have already been vaccinated with BCG. This is the
      first Phase II study of AERAS-402 in infants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Adverse Events Collected Per Subject</measure>
    <time_frame>Up to 24 months post vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse Events (AEs) are recorded for 28 days post vaccination Serious Adverse Events (SAEs) are recorded for the entire study period to assess the safety profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Cells Expressing Various Cytokines Will be Measured by Intracellular Cytokine Staining (ICS) in All Subjects</measure>
    <time_frame>28 days post last vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the immunogenicity of AERAS-402 compared to controls, flow cytometric ICS of CD4 and CD8 T cells producing any of three cytokines (IFN-γ, TNF-α, and/or IL-2) alone or in combination after stimulation with a peptide pool of mycobacterial peptides. Dimethylsulfoxide (DMSO) subtracted responses are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon-gamma (IFN-gamma) Enzyme-linked Immunospot (ELISpot) Response: Spot Forming Units/10^6 PBMC According to ELISpot Assay</measure>
    <time_frame>28 days post last vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the immunogenicity of AERAS-402 compared to controls. ELISpot assay of specific T cell responses after stimulation with a peptide pool of mycobacterial peptides. Values presented have been corrected for background readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antigen-specific Antibody Response - Mean Optical Density (Mean OD)</measure>
    <time_frame>28 day post last vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the immunogenicity of AERAS-402 compared to controls by ELISA Assay for Antigen-specific Antibody Response. Median responses of individual Mean OD (absorbance at 450nm) by study group is presented. Higher OD values suggests the presence of antibody to each of the Mtb antigens (Ag85A, Ag85B and TB10.4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Converting From a Negative QuantiFERON Test (QFT) to Positive QFT After Vaccination</measure>
    <time_frame>up to 24 months post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the proportion of on-study QuantiFERON conversions from negative to positive in infants that received AERAS-402 compared to controls. A QFT value of on &gt;= 0.35IU/mL was considered positive for this study.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">487</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Dose Finding Gr 1 placebo x 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received two doses (x2) of placebo (sterile buffer) on study days 0 and 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Finding Gr 2 AERAS-402 (1.5 x 10^10 vp) x2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two doses (x2) of AERAS-402 (1.5 x 10^10 vp) on study days 0 and 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Finding Gr 3 AERAS-402 (3.0 x 10^10 vp) x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two doses (x2) of AERAS-402 (3.0 x 10^10 vp) on study days 0 and 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Finding Gr 4 AERAS-402 (1.0 x 10^11 vp) x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two doses (x2) of AERAS-402 (1.0 x 10^11 vp) on study days 0 and 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expanded Safety Phase Gr 5 AERAS-402 (1.0 X 10^11 vp) x 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses (x3) of AERAS-402 (1.0 X 10^11 vp) on days 0, 28 and 280.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expanded Safety Phase Gr 5 Placebo x3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received 3 doses (x3) of placebo (sterile buffer) on days 0, 28 and 280.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AERAS-402 1.5 x 10^10 vp</intervention_name>
    <arm_group_label>Dose Finding Gr 2 AERAS-402 (1.5 x 10^10 vp) x2</arm_group_label>
    <arm_group_label>Expanded Safety Phase Gr 5 AERAS-402 (1.0 X 10^11 vp) x 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AERAS-402 3.0 x 10^10 vp</intervention_name>
    <arm_group_label>Dose Finding Gr 3 AERAS-402 (3.0 x 10^10 vp) x 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AERAS-402 1.0 x 10^11 vp</intervention_name>
    <arm_group_label>Dose Finding Gr 4 AERAS-402 (1.0 x 10^11 vp) x 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Dose Finding Gr 1 placebo x 2</arm_group_label>
    <arm_group_label>Expanded Safety Phase Gr 5 Placebo x3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parent/legal guardian has completed the written informed consent process

          2. Is age greater than or equal to 112 days (16 weeks) and less than or equal 182 days
             (26 weeks) on Study Day 0

          3. Has general good health, confirmed by medical history and physical examination

          4. Is up to date on all Expanded Program of Immunization (EPI) immunizations for his/her
             age with a minimum of 14 days between the last EPI vaccination and administration of
             study vaccine on Study Day 0

          5. Has ability to complete follow-up period of 728 days as required by the protocol

          6. Parent/legal guardian is able and willing to stay in contact with the study site for
             the duration of the study and to provide updated contact information as necessary,
             and has no current plans to move from the study area for the duration of the study

          7. Has completed simultaneous enrollment in Aeras Vaccine Development Registry protocol

          8. Had BCG vaccination ≥ 3 months prior to randomization documented by medical card

        Exclusion Criteria:

          1. Acute illness, evidence of any significant active infection or temperature &gt;=37.5°C
             on the day of randomization

          2. Used immunosuppressive medication within 45 days before entry into the study (inhaled
             and topical corticosteroids are permitted)

          3. Received immunoglobulin or blood products within 45 days before entry into the study

          4. Ever received any investigational drug therapy or investigational vaccine

          5. History or laboratory evidence of individual immunodeficiency virus (HIV-1) infection

          6. History of allergic disease or reactions to any component of the study vaccine

          7. Previous medical history that may compromise the safety of the participant in the
             study

          8. Evidence of a new acute illness that may compromise the safety of the participant in
             the study

          9. Inability to discontinue daily medications during the study

         10. History or evidence of any systemic disease on physical examination or any acute or
             chronic illness that may interfere with the evaluation of the safety or
             immunogenicity of the vaccine, e.g., including masses between the leg and abdomen
             (e.g., inguinal hernia or lymphadenopathy)

         11. History or evidence of active tuberculosis

         12. A positive QuantiFERON®-TB Gold In-Tube test

         13. A household contact with active TB disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>112 Days</minimum_age>
    <maximum_age>182 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker</last_name>
    <role>Study Director</role>
    <affiliation>Aeras</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boro Heath Center</name>
      <address>
        <city>Boro</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KEMRI/CDC Research and Public Heath Collaboration</name>
      <address>
        <city>Kisumu</city>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siaya District Hospital</name>
      <address>
        <city>Siaya</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CISM: Centro de Investigacao em Saude de Manhica</name>
      <address>
        <city>Manhica</city>
        <zip>1929</zip>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU) Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SATVI: Worcester</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Mozambique</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 12, 2015</lastchanged_date>
  <firstreceived_date>September 7, 2010</firstreceived_date>
  <firstreceived_results_date>June 10, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Prevention of Tuberculosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Finding - Group 1</title>
          <description>Subjects enrolled in Study Group 1 will receive two doses of placebo once on Study Day 0 and again on Study Day 28.
Placebo: Sterile buffer</description>
        </group>
        <group group_id="P2">
          <title>Dose Finding - Group 2</title>
          <description>Subjects enrolled in Study Group 2 will receive two doses of AERAS-402 (1.5 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.5 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
        </group>
        <group group_id="P3">
          <title>Dose Finding - Group 3</title>
          <description>Subjects enrolled in Study Group 3 will receive two doses of AERAS-402 (3.0 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 3.0 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
        </group>
        <group group_id="P4">
          <title>Dose Finding - Group 4</title>
          <description>Subjects enrolled in Study Group 4 will receive two doses of AERAS-402 (1.0 x 10^11 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
        </group>
        <group group_id="P5">
          <title>Expanded Safety Phase - Group 5</title>
          <description>Subjects received 3 doses of AERAS-402 (1 X 10^11 vp) on days 0, 28 and 280.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
        </group>
        <group group_id="P6">
          <title>Expanded Safety Phase - Group 5 Placebo</title>
          <description>Subjects received 3 doses of placebo on days 0, 28 and 280.
Placebo: Sterile buffer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="140"/>
                <participants group_id="P6" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="125"/>
                <participants group_id="P6" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Finding - Group 1</title>
          <description>Subjects enrolled in Study Group 1 will receive two doses of placebo once on Study Day 0 and again on Study Day 28.
Placebo: Sterile buffer</description>
        </group>
        <group group_id="B2">
          <title>Dose Finding - Group 2</title>
          <description>Subjects enrolled in Study Group 2 will receive two doses of AERAS-402 (1.5 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.5 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
        </group>
        <group group_id="B3">
          <title>Dose Finding - Group 3</title>
          <description>Subjects enrolled in Study Group 3 will receive two doses of AERAS-402 (3.0 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 3.0 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
        </group>
        <group group_id="B4">
          <title>Dose Finding - Group 4</title>
          <description>Subjects enrolled in Study Group 4 will receive two doses of AERAS-402 (1.0 x 10^11 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
        </group>
        <group group_id="B5">
          <title>Expanded Safety Phase - Group 5</title>
          <description>Subjects received 3 doses of AERAS-402 (1 X 10^11 vp) on days 0, 28 and 280.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
        </group>
        <group group_id="B6">
          <title>Expanded Safety Phase - Group 5 Placebo</title>
          <description>Subjects received 3 doses of placebo on days 0, 28 and 280.
Placebo: Sterile buffer</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="51"/>
                <measurement group_id="B4" value="52"/>
                <measurement group_id="B5" value="140"/>
                <measurement group_id="B6" value="141"/>
                <measurement group_id="B7" value="487"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>≥112 days (16 weeks) and ≤182 days (26 weeks) on Study Day 0</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Age at Study Day 0 in Days</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="145.3" spread="18.15"/>
                <measurement group_id="B2" value="144.5" spread="17.83"/>
                <measurement group_id="B3" value="138.6" spread="19.45"/>
                <measurement group_id="B4" value="149.1" spread="21.44"/>
                <measurement group_id="B5" value="145.2" spread="19.98"/>
                <measurement group_id="B6" value="150.2" spread="20.22"/>
                <measurement group_id="B7" value="146.3" spread="19.97"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="30"/>
                <measurement group_id="B4" value="20"/>
                <measurement group_id="B5" value="68"/>
                <measurement group_id="B6" value="57"/>
                <measurement group_id="B7" value="217"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="21"/>
                <measurement group_id="B4" value="32"/>
                <measurement group_id="B5" value="72"/>
                <measurement group_id="B6" value="84"/>
                <measurement group_id="B7" value="270"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="41"/>
                <measurement group_id="B4" value="43"/>
                <measurement group_id="B5" value="102"/>
                <measurement group_id="B6" value="98"/>
                <measurement group_id="B7" value="370"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Coloured</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="9"/>
                <measurement group_id="B5" value="38"/>
                <measurement group_id="B6" value="43"/>
                <measurement group_id="B7" value="117"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
                <measurement group_id="B6" value="0"/>
                <measurement group_id="B7" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
                <measurement group_id="B6" value="0"/>
                <measurement group_id="B7" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
                <measurement group_id="B6" value="0"/>
                <measurement group_id="B7" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Two sites in South Africa - Worcester and Soweto. Soweto only participated in Group 5.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Mozambique</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="4"/>
                <measurement group_id="B5" value="0"/>
                <measurement group_id="B6" value="0"/>
                <measurement group_id="B7" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>South Africa</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="12"/>
                <measurement group_id="B4" value="12"/>
                <measurement group_id="B5" value="59"/>
                <measurement group_id="B6" value="59"/>
                <measurement group_id="B7" value="166"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Kenya</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="36"/>
                <measurement group_id="B4" value="36"/>
                <measurement group_id="B5" value="70"/>
                <measurement group_id="B6" value="71"/>
                <measurement group_id="B7" value="285"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>South Africa</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="11"/>
                <measurement group_id="B6" value="11"/>
                <measurement group_id="B7" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events Collected Per Subject</title>
        <description>Adverse Events (AEs) are recorded for 28 days post vaccination Serious Adverse Events (SAEs) are recorded for the entire study period to assess the safety profile</description>
        <time_frame>Up to 24 months post vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Subjects who received at least one vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Finding - Group 1</title>
            <description>Subjects enrolled in Study Group 1 will receive two doses of placebo once on Study Day 0 and again on Study Day 28.
Placebo: Sterile buffer</description>
          </group>
          <group group_id="O2">
            <title>Dose Finding - Group 2</title>
            <description>Subjects enrolled in Study Group 2 will receive two doses of AERAS-402 (1.5 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.5 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O3">
            <title>Dose Finding - Group 3</title>
            <description>Subjects enrolled in Study Group 3 will receive two doses of AERAS-402 (3.0 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 3.0 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O4">
            <title>Dose Finding - Group 4</title>
            <description>Subjects enrolled in Study Group 4 will receive two doses of AERAS-402 (1.0 x 10^11 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O5">
            <title>Expanded Safety Phase - Group 5</title>
            <description>Subjects received 3 doses of AERAS-402 (1 X 10^11 vp) on days 0, 28 and 280.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O6">
            <title>Expanded Safety Phase - Group 5 Placebo</title>
            <description>Subjects received 3 doses of placebo on days 0, 28 and 280.
Placebo: Sterile buffer</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="51"/>
                  <measurement group_id="O4" value="52"/>
                  <measurement group_id="O5" value="140"/>
                  <measurement group_id="O6" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adverse Events Collected Per Subject</title>
            <description>Adverse Events (AEs) are recorded for 28 days post vaccination Serious Adverse Events (SAEs) are recorded for the entire study period to assess the safety profile</description>
            <units>percentage of subjects with an AE</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94.2"/>
                  <measurement group_id="O2" value="96.1"/>
                  <measurement group_id="O3" value="100.0"/>
                  <measurement group_id="O4" value="100.0"/>
                  <measurement group_id="O5" value="100.0"/>
                  <measurement group_id="O6" value="98.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Cells Expressing Various Cytokines Will be Measured by Intracellular Cytokine Staining (ICS) in All Subjects</title>
        <description>To evaluate the immunogenicity of AERAS-402 compared to controls, flow cytometric ICS of CD4 and CD8 T cells producing any of three cytokines (IFN-γ, TNF-α, and/or IL-2) alone or in combination after stimulation with a peptide pool of mycobacterial peptides. Dimethylsulfoxide (DMSO) subtracted responses are presented.</description>
        <time_frame>28 days post last vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Groups 1–4: Subjects who received both vaccinations as randomized. Group 5: Subjects who received all three study vaccinations as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Finding - Group 1</title>
            <description>Subjects enrolled in Study Group 1 will receive two doses of placebo once on Study Day 0 and again on Study Day 28.
Placebo: Sterile buffer</description>
          </group>
          <group group_id="O2">
            <title>Dose Finding - Group 2</title>
            <description>Subjects enrolled in Study Group 2 will receive two doses of AERAS-402 (1.5 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.5 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O3">
            <title>Dose Finding - Group 3</title>
            <description>Subjects enrolled in Study Group 3 will receive two doses of AERAS-402 (3.0 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 3.0 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O4">
            <title>Dose Finding - Group 4</title>
            <description>Subjects enrolled in Study Group 4 will receive two doses of AERAS-402 (1.0 x 10^11 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O5">
            <title>Expanded Safety Phase - Group 5</title>
            <description>Subjects received 3 doses of AERAS-402 (1 X 10^11 vp) on days 0, 28 and 280.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O6">
            <title>Expanded Safety Phase - Group 5 Placebo</title>
            <description>Subjects received 3 doses of placebo on days 0, 28 and 280.
Placebo: Sterile buffer</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="42"/>
                  <measurement group_id="O4" value="46"/>
                  <measurement group_id="O5" value="50"/>
                  <measurement group_id="O6" value="61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Cells Expressing Various Cytokines Will be Measured by Intracellular Cytokine Staining (ICS) in All Subjects</title>
            <description>To evaluate the immunogenicity of AERAS-402 compared to controls, flow cytometric ICS of CD4 and CD8 T cells producing any of three cytokines (IFN-γ, TNF-α, and/or IL-2) alone or in combination after stimulation with a peptide pool of mycobacterial peptides. Dimethylsulfoxide (DMSO) subtracted responses are presented.</description>
            <units>percentage of Tcell response</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Ag85A CD4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  <measurement group_id="O2" value="0.01" lower_limit="0.00" upper_limit="0.03"/>
                  <measurement group_id="O3" value="0.02" lower_limit="0.01" upper_limit="0.03"/>
                  <measurement group_id="O4" value="0.02" lower_limit="0.01" upper_limit="0.04"/>
                  <measurement group_id="O5" value="0.02" lower_limit="0.01" upper_limit="0.04"/>
                  <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="0.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ag85A CD8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  <measurement group_id="O2" value="0.01" lower_limit="0.00" upper_limit="0.04"/>
                  <measurement group_id="O3" value="0.01" lower_limit="0.00" upper_limit="0.04"/>
                  <measurement group_id="O4" value="0.02" lower_limit="0.00" upper_limit="0.04"/>
                  <measurement group_id="O5" value="0.04" lower_limit="0.01" upper_limit="0.06"/>
                  <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="0.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ag85B CD4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.01"/>
                  <measurement group_id="O2" value="0.02" lower_limit="0.01" upper_limit="0.03"/>
                  <measurement group_id="O3" value="0.02" lower_limit="0.01" upper_limit="0.03"/>
                  <measurement group_id="O4" value="0.03" lower_limit="0.01" upper_limit="0.04"/>
                  <measurement group_id="O5" value="0.01" lower_limit="0.01" upper_limit="0.03"/>
                  <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="0.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ag85B CD8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.01"/>
                  <measurement group_id="O2" value="0.04" lower_limit="0.02" upper_limit="0.08"/>
                  <measurement group_id="O3" value="0.03" lower_limit="0.01" upper_limit="0.05"/>
                  <measurement group_id="O4" value="0.04" lower_limit="0.02" upper_limit="0.07"/>
                  <measurement group_id="O5" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                  <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TB10.4 CD4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.01" lower_limit="0.00" upper_limit="0.01"/>
                  <measurement group_id="O2" value="0.01" lower_limit="0.00" upper_limit="0.01"/>
                  <measurement group_id="O3" value="0.01" lower_limit="0.00" upper_limit="0.03"/>
                  <measurement group_id="O4" value="0.01" lower_limit="0.01" upper_limit="0.02"/>
                  <measurement group_id="O5" value="0.01" lower_limit="0.00" upper_limit="0.01"/>
                  <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="0.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TB10.4 CD8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.01"/>
                  <measurement group_id="O2" value="0.01" lower_limit="0.00" upper_limit="0.01"/>
                  <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.01"/>
                  <measurement group_id="O4" value="0.01" lower_limit="0.00" upper_limit="0.02"/>
                  <measurement group_id="O5" value="0.01" lower_limit="0.00" upper_limit="0.01"/>
                  <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interferon-gamma (IFN-gamma) Enzyme-linked Immunospot (ELISpot) Response: Spot Forming Units/10^6 PBMC According to ELISpot Assay</title>
        <description>To evaluate the immunogenicity of AERAS-402 compared to controls. ELISpot assay of specific T cell responses after stimulation with a peptide pool of mycobacterial peptides. Values presented have been corrected for background readings.</description>
        <time_frame>28 days post last vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Groups 1 and 4: Subjects who received both vaccinations as randomized (assays were not done for Groups 2 and 3).
Group 5: Subjects who received all three study vaccinations as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Finding - Group 1</title>
            <description>Subjects enrolled in Study Group 1 will receive two doses of placebo once on Study Day 0 and again on Study Day 28.
Placebo: Sterile buffer</description>
          </group>
          <group group_id="O2">
            <title>Dose Finding - Group 2</title>
            <description>Subjects enrolled in Study Group 2 will receive two doses of AERAS-402 (1.5 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.5 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O3">
            <title>Dose Finding - Group 3</title>
            <description>Subjects enrolled in Study Group 3 will receive two doses of AERAS-402 (3.0 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 3.0 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O4">
            <title>Dose Finding - Group 4</title>
            <description>Subjects enrolled in Study Group 4 will receive two doses of AERAS-402 (1.0 x 10^11 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O5">
            <title>Expanded Safety Phase - Group 5</title>
            <description>Subjects received 3 doses of AERAS-402 (1 X 10^11 vp) on days 0, 28 and 280.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O6">
            <title>Expanded Safety Phase - Group 5 Placebo</title>
            <description>Subjects received 3 doses of placebo on days 0, 28 and 280.
Placebo: Sterile buffer</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="34"/>
                  <measurement group_id="O5" value="43"/>
                  <measurement group_id="O6" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Interferon-gamma (IFN-gamma) Enzyme-linked Immunospot (ELISpot) Response: Spot Forming Units/10^6 PBMC According to ELISpot Assay</title>
            <description>To evaluate the immunogenicity of AERAS-402 compared to controls. ELISpot assay of specific T cell responses after stimulation with a peptide pool of mycobacterial peptides. Values presented have been corrected for background readings.</description>
            <units>SFU/10^6 PBMC</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Ag85A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.00" lower_limit="2.50" upper_limit="6.67"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4" value="87.92" lower_limit="74.17" upper_limit="156.67"/>
                  <measurement group_id="O5" value="98.33" lower_limit="70.00" upper_limit="151.67"/>
                  <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="3.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ag85B</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.42" lower_limit="0.00" upper_limit="5.00"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4" value="127.08" lower_limit="70.83" upper_limit="285.00"/>
                  <measurement group_id="O5" value="65.00" lower_limit="51.67" upper_limit="133.33"/>
                  <measurement group_id="O6" value="0.83" lower_limit="0.00" upper_limit="5.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TB10.4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.42" lower_limit="0.83" upper_limit="11.67"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4" value="26.67" lower_limit="19.17" upper_limit="49.17"/>
                  <measurement group_id="O5" value="17.50" lower_limit="11.67" upper_limit="28.33"/>
                  <measurement group_id="O6" value="3.33" lower_limit="1.67" upper_limit="6.67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antigen-specific Antibody Response - Mean Optical Density (Mean OD)</title>
        <description>To evaluate the immunogenicity of AERAS-402 compared to controls by ELISA Assay for Antigen-specific Antibody Response. Median responses of individual Mean OD (absorbance at 450nm) by study group is presented. Higher OD values suggests the presence of antibody to each of the Mtb antigens (Ag85A, Ag85B and TB10.4).</description>
        <time_frame>28 day post last vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Groups 1 and 4: Subjects who received both vaccinations as randomized (assays were not done for Ag85A and TB10.4).
Assays were not done for groups 2 and 3 for any antigen. Group 5: Subjects who received all three study vaccinations as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Finding - Group 1</title>
            <description>Subjects enrolled in Study Group 1 will receive two doses of placebo once on Study Day 0 and again on Study Day 28.
Placebo: Sterile buffer</description>
          </group>
          <group group_id="O2">
            <title>Dose Finding - Group 2</title>
            <description>Subjects enrolled in Study Group 2 will receive two doses of AERAS-402 (1.5 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.5 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O3">
            <title>Dose Finding - Group 3</title>
            <description>Subjects enrolled in Study Group 3 will receive two doses of AERAS-402 (3.0 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 3.0 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O4">
            <title>Dose Finding - Group 4</title>
            <description>Subjects enrolled in Study Group 4 will receive two doses of AERAS-402 (1.0 x 10^11 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O5">
            <title>Expanded Safety Phase - Group 5</title>
            <description>Subjects received 3 doses of AERAS-402 (1 X 10^11 vp) on days 0, 28 and 280.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O6">
            <title>Expanded Safety Phase - Group 5 Placebo</title>
            <description>Subjects received 3 doses of placebo on days 0, 28 and 280.
Placebo: Sterile buffer</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="32"/>
                  <measurement group_id="O5" value="18"/>
                  <measurement group_id="O6" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antigen-specific Antibody Response - Mean Optical Density (Mean OD)</title>
            <description>To evaluate the immunogenicity of AERAS-402 compared to controls by ELISA Assay for Antigen-specific Antibody Response. Median responses of individual Mean OD (absorbance at 450nm) by study group is presented. Higher OD values suggests the presence of antibody to each of the Mtb antigens (Ag85A, Ag85B and TB10.4).</description>
            <units>Optical Density</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Ag85A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA">This group was not analyzed.</measurement>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4" value="NA">This group was not analyzed.</measurement>
                  <measurement group_id="O5" value="1.34" lower_limit="1.08" upper_limit="2.37"/>
                  <measurement group_id="O6" value="0.20" lower_limit="0.14" upper_limit="0.30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ag85B</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.26" lower_limit="0.12" upper_limit="0.38"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4" value="2.15" lower_limit="1.80" upper_limit="2.53"/>
                  <measurement group_id="O5" value="2.17" lower_limit="1.95" upper_limit="3.04"/>
                  <measurement group_id="O6" value="0.37" lower_limit="0.28" upper_limit="0.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TB10.4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA">This group was not analyzed.</measurement>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4" value="NA">This group was not analyzed.</measurement>
                  <measurement group_id="O5" value="0.94" lower_limit="0.39" upper_limit="1.50"/>
                  <measurement group_id="O6" value="0.34" lower_limit="0.25" upper_limit="0.46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Converting From a Negative QuantiFERON Test (QFT) to Positive QFT After Vaccination</title>
        <description>To evaluate the proportion of on-study QuantiFERON conversions from negative to positive in infants that received AERAS-402 compared to controls. A QFT value of on &gt;= 0.35IU/mL was considered positive for this study.</description>
        <time_frame>up to 24 months post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects who received at least one vaccination and had results at baseline and end of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Finding - Group 1</title>
            <description>Subjects enrolled in Study Group 1 will receive two doses of placebo once on Study Day 0 and again on Study Day 28.
Placebo: Sterile buffer</description>
          </group>
          <group group_id="O2">
            <title>Dose Finding - Group 2</title>
            <description>Subjects enrolled in Study Group 2 will receive two doses of AERAS-402 (1.5 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.5 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O3">
            <title>Dose Finding - Group 3</title>
            <description>Subjects enrolled in Study Group 3 will receive two doses of AERAS-402 (3.0 x 10^10 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 3.0 x 10^10 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O4">
            <title>Dose Finding - Group 4</title>
            <description>Subjects enrolled in Study Group 4 will receive two doses of AERAS-402 (1.0 x 10^11 vp) once on Study Day 0 and again on Study Day 28.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O5">
            <title>Expanded Safety Phase - Group 5</title>
            <description>Subjects received 3 doses of AERAS-402 (1 X 10^11 vp) on days 0, 28 and 280.
AERAS-402 1.0 x 10^11 vp: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens.</description>
          </group>
          <group group_id="O6">
            <title>Expanded Safety Phase - Group 5 Placebo</title>
            <description>Subjects received 3 doses of placebo on days 0, 28 and 280.
Placebo: Sterile buffer</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="44"/>
                  <measurement group_id="O3" value="43"/>
                  <measurement group_id="O4" value="47"/>
                  <measurement group_id="O5" value="124"/>
                  <measurement group_id="O6" value="128"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects Converting From a Negative QuantiFERON Test (QFT) to Positive QFT After Vaccination</title>
            <description>To evaluate the proportion of on-study QuantiFERON conversions from negative to positive in infants that received AERAS-402 compared to controls. A QFT value of on &gt;= 0.35IU/mL was considered positive for this study.</description>
            <units>% converting from QFT neg to pos</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="13.6"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="4.3"/>
                  <measurement group_id="O5" value="2.4"/>
                  <measurement group_id="O6" value="4.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dose Finding - Group 1</title>
          <description>Subjects received two doses of placebo (sterile buffer) on study days 0 and 28.</description>
        </group>
        <group group_id="E2">
          <title>Dose Finding - Group 2</title>
          <description>Subjects received two doses of AERAS-402 (1.5 x 10^10 vp) on study days 0 and 28.</description>
        </group>
        <group group_id="E3">
          <title>Dose Finding - Group 3</title>
          <description>Subjects received two doses of AERAS-402 (3.0 x 10^10 vp) on study days 0 and 28.</description>
        </group>
        <group group_id="E4">
          <title>Dose Finding - Group 4</title>
          <description>Subjects received two doses of AERAS-402 (1.0 x 10^11 vp) on study days 0 and 28.</description>
        </group>
        <group group_id="E5">
          <title>Expanded Safety Phase - Group 5</title>
          <description>Subjects received 3 doses of AERAS-402 (1.0 X 10^11 vp) on days 0, 28 and 280.</description>
        </group>
        <group group_id="E6">
          <title>Expanded Safety Phase - Group 5 Placebo</title>
          <description>Subjects received 3 doses of placebo (sterile buffer) on days 0, 28 and 280.
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="140"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Brain malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E6" events="14" subjects_affected="11" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E5" events="16" subjects_affected="14" subjects_at_risk="140"/>
                <counts group_id="E6" events="18" subjects_affected="12" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="140"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Salmonella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Staphylococcal scalded skin syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="136" subjects_at_risk="140"/>
                <counts group_id="E6" subjects_affected="139" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E5" events="77" subjects_affected="47" subjects_at_risk="140"/>
                <counts group_id="E6" events="70" subjects_affected="48" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E5" events="36" subjects_affected="30" subjects_at_risk="140"/>
                <counts group_id="E6" events="26" subjects_affected="20" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="49" subjects_affected="29" subjects_at_risk="52"/>
                <counts group_id="E2" events="53" subjects_affected="30" subjects_at_risk="51"/>
                <counts group_id="E3" events="50" subjects_affected="30" subjects_at_risk="51"/>
                <counts group_id="E4" events="46" subjects_affected="28" subjects_at_risk="52"/>
                <counts group_id="E5" events="151" subjects_affected="87" subjects_at_risk="140"/>
                <counts group_id="E6" events="103" subjects_affected="71" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E4" events="19" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E5" events="59" subjects_affected="40" subjects_at_risk="140"/>
                <counts group_id="E6" events="22" subjects_affected="16" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" events="20" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E5" events="43" subjects_affected="37" subjects_at_risk="140"/>
                <counts group_id="E6" events="19" subjects_affected="18" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E5" events="42" subjects_affected="30" subjects_at_risk="140"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E4" events="54" subjects_affected="37" subjects_at_risk="52"/>
                <counts group_id="E5" events="191" subjects_affected="104" subjects_at_risk="140"/>
                <counts group_id="E6" events="28" subjects_affected="23" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="51"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E4" events="22" subjects_affected="17" subjects_at_risk="52"/>
                <counts group_id="E5" events="60" subjects_affected="46" subjects_at_risk="140"/>
                <counts group_id="E6" events="14" subjects_affected="12" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E5" events="76" subjects_affected="60" subjects_at_risk="140"/>
                <counts group_id="E6" events="22" subjects_affected="19" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="14" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E5" events="25" subjects_affected="24" subjects_at_risk="140"/>
                <counts group_id="E6" events="21" subjects_affected="20" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E3" events="21" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E4" events="22" subjects_affected="17" subjects_at_risk="52"/>
                <counts group_id="E5" events="50" subjects_affected="34" subjects_at_risk="140"/>
                <counts group_id="E6" events="48" subjects_affected="35" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E4" events="25" subjects_affected="18" subjects_at_risk="52"/>
                <counts group_id="E5" events="30" subjects_affected="26" subjects_at_risk="140"/>
                <counts group_id="E6" events="21" subjects_affected="20" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="47" subjects_affected="31" subjects_at_risk="52"/>
                <counts group_id="E2" events="46" subjects_affected="32" subjects_at_risk="51"/>
                <counts group_id="E3" events="55" subjects_affected="36" subjects_at_risk="51"/>
                <counts group_id="E4" events="55" subjects_affected="37" subjects_at_risk="52"/>
                <counts group_id="E5" events="248" subjects_affected="117" subjects_at_risk="140"/>
                <counts group_id="E6" events="214" subjects_affected="114" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="140"/>
                <counts group_id="E6" events="19" subjects_affected="19" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E5" events="37" subjects_affected="35" subjects_at_risk="140"/>
                <counts group_id="E6" events="34" subjects_affected="28" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="15" subjects_affected="13" subjects_at_risk="140"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="52"/>
                <counts group_id="E5" events="38" subjects_affected="36" subjects_at_risk="140"/>
                <counts group_id="E6" events="37" subjects_affected="32" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="51"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E5" events="20" subjects_affected="18" subjects_at_risk="140"/>
                <counts group_id="E6" events="24" subjects_affected="21" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="140"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Protein urine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>White blood cells urine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="51" subjects_affected="32" subjects_at_risk="52"/>
                <counts group_id="E2" events="52" subjects_affected="28" subjects_at_risk="51"/>
                <counts group_id="E3" events="51" subjects_affected="31" subjects_at_risk="51"/>
                <counts group_id="E4" events="42" subjects_affected="30" subjects_at_risk="52"/>
                <counts group_id="E5" events="102" subjects_affected="61" subjects_at_risk="140"/>
                <counts group_id="E6" events="96" subjects_affected="56" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="140"/>
                <counts group_id="E6" events="16" subjects_affected="15" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E5" events="32" subjects_affected="28" subjects_at_risk="140"/>
                <counts group_id="E6" events="48" subjects_affected="39" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Product Director</name_or_title>
      <organization>Aeras</organization>
      <phone>301-547-2919</phone>
      <email>blandry@aeras.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
